Zafgen shelves another drug; chief medical officer exits
The bad news keeps coming for Boston biotech Zafgen Inc., which revealed Monday that it is shelving another drug due to safety concerns.
Zafgen (Nasdaq: ZFGN) has hit multiple dead ends while attempting to treat metabolic diseases such as Type 2 diabetes and Prader-Willi Syndrome by inhibiting an enzyme known as MetAP2.
Testing on the company's lead drug for Type 2 diabetes, ZGN-1061, remains on a clinical hold in the U.S. nearly six months after the FDA voiced concerns about a potential cardiovascular…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Health Management | Heart | Prader-Willi Syndrome